17:39 , Mar 3, 2017 |  BC Week In Review  |  Clinical News

Supinoxin: Ph IIa started

Rexahn began an open-label, U.S. Phase IIa trial to evaluate Supinoxin in up to 50 patients who have failed prior therapies. Rexahn Pharmaceuticals Inc. (NYSE-M:RNN), Rockville, Md.  Product: Supinoxin (RX-5902)   Business: Cancer   Molecular target:...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DEAD box helicase 5 (DDX5; p68)

Autoimmune disease INDICATION: Inflammatory bowel disease (IBD) Mouse studies suggest inhibiting DDX5 could help treat IBD. In an adoptive T cell transfer mouse model of IBD, mice receiving DDX5-deficient T cells did not develop colitis and had...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

Supinoxin: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation, U.S. Phase I trial in about 20 patients with advanced or metastatic solid tumors showed that 25, 50 and 100 mg doses of oral Supinoxin given on days 1,...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Clinical News

Supinoxin: Phase I started

Rexahn began a dose-escalation Phase I trial to evaluate oral RX-5902 in patients with solid tumors. Rexahn Pharmaceuticals Inc. (NYSE-M:RNN), Rockville, Md.   Product: Supinoxin ( RX-5902)   Business: Cancer   Molecular target: DEAD box polypeptide...
08:00 , Feb 6, 2012 |  BC Week In Review  |  Clinical News

Rexahn preclinical data

In vitro, RX-5902 inhibited various human cancer cell lines with IC50 values ranging from of 12-24 nM. Additionally, the small molecule inhibitor of DEAD box polypeptide 5 (DDX5; p68) RNA helicase and G2/M cell cycle...
08:00 , Jan 7, 2010 |  BC Innovations  |  Tools & Techniques

Going live with aptamers

Researchers at the Duke University School of Medicine think they have improved upon a 20-year-old technology for selecting target-specific aptamers in vitro by making it work in vivo.1 Using the approach, the group identified an...
08:00 , Dec 17, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens In vivo selection of tumor-targeting RNA aptamers In vivo selection of tumor-targeting RNA aptamers could be useful for...